Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs

Pharmacological Research

Volumn 107, Issue , 2016, Pages 249-275

  Roskoski, Robert ^a  

^a Blue Ridge Institute for Medical Research   (United States)

Author keywords

ATP binding site; Breast cancer; Catalytic spine; K E D D; Protein kinase structure; Regulatory spine

Indexed keywords

7 HYDROXYSTAUROSPORINE; ABEMACICLIB; ANTINEOPLASTIC AGENT; AT 7519; CYCLIN A; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DINACICLIB; FLAVOPIRIDOL; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PALBOCICLIB; RIBOCICLIB; RIVICICLIB; ROSCOVITINE; UNCLASSIFIED DRUG; VENETOCLAX; CYCLIN DEPENDENT KINASE INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

BINDING SITE; BREAST CANCER; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC50; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLIN-DEPENDENT KINASES; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84962019862     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.03.012     Document Type: Review

References (220)

1. M.D. Malumbres, and M. Barbacid Mammalian cyclin-dependent kinases Trends Biochem. Sci. 30 2005 630 641
2. M. Malumbres, and M. Barbacid To cycle or not to cycle: a critical decision in cancer Nat. Rev. Cancer 1 2001 222 231
3. M. Malumbres Cyclin-dependent kinases Genome Biol. 15 2014 122
4. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
5. M. Peyressatre, C. Prével, M. Pellerano, and M.C. Morris Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors Cancers (Basel) 7 2015 179 237
6. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1677
7. T. Arooz, C.H. Yam, W.Y. Siu, A. Lau, K.K. Li, and R.Y. Poon On the concentrations of cyclins and cyclin-dependent kinases in extracts of cultured human cells Biochemistry 39 2000 9494 9501
8. K.I. Nakayama, and K. Nakayama Ubiquitin ligases: cell-cycle control and cancer Nat. Rev. Cancer 6 2006 369 381
9. S. Lim, and P. Kaldis Cdks, cyclins and CKIs: roles beyond cell cycle regulation Development 140 2013 3079 3093
10. F. Bassermann, R. Eichner, and M. Pagano The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer Biochim. Biophys. Acta 1843 2014 150 162
11. W. Kolch, M. Halasz, M. Granovskaya, and B.N. Kholodenko The dynamic control of signal transduction networks in cancer cells Nat. Rev. Cancer 15 2015 515 527
12. M. Goldstein, and M.B. Kastan The DNA damage response: implications for tumor responses to radiation and chemotherapy Annu. Rev. Med. 66 2015 129 143
13. A.M. Narasimha, M. Kaulich, G.S. Shapiro, Y.J. Choi, P. Sicinski, and S.F. Dowdy Cyclin D activates the Rb tumor suppressor by mono-phosphorylation Elife 2014 3
14. J.M. Trimarchi, and J.A. Lees Sibling rivalry in the E2F family Nat. Rev. Mol. Cell Biol. 3 2002 11 20
15. L. Anders, N. Ke, P. Hydbring, Y.J. Choi, H.R. Widlund, J.M. Chick, and et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells Cancer Cell 15 20 2011 620 634
16. N.G. Starostina, and E.T. Kipreos Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors Trends Cell Biol. 22 2012 33 41
17. INK4a in cancer and aging Mol. Cancer Res. 12 2014 167 183
18. E.T. Cánepa, M.E. Scassa, J.M. Ceruti, M.C. Marazita, A.L. Carcagno, P.F. Sirkin, and et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions IUBMB Life 59 2007 419 426
19. Ink4d Mol. Cell. Biol. 21 2001 3244 3255
20. F. Zindy, J.J. Cunningham, C.J. Sherr, S. Jogal, R.J. Smeyne, and M.F. Roussel Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases Proc. Natl. Acad. Sci. U. S. A. 96 1999 13462 13467
21. J. Cicenas, K. Kalyan, A. Sorokinas, A. Jatulyte, D. Valiunas, A. Kaupinis, and et al. Highlights of the latest advances in research on CDK inhibitors Cancers (Basel) 6 2014 2224 2242
22. L. Santo, K.T. Siu, and N. Raje Targeting cyclin-dependent kinases and cell cycle progression in human cancers Semin. Oncol. 42 2015 788 800
23. E.A. Musgrove, C.E. Caldon, J. Barraclough, A. Stone, and R.L. Sutherland Cyclin D as a therapeutic target in cancer Nat. Rev. Cancer 11 2011 558 572
24. T. Santarius, J. Shipley, D. Brewer, M.R. Stratton, and C.S. Cooper A census of amplified and overexpressed human cancer genes Nat. Rev. Cancer 10 2010 59 64
25. M. Schwaederlé, G.A. Daniels, D.E. Piccioni, P.T. Fanta, R.B. Schwab, K.A. Shimabukuro, and et al. Cyclin alterations in diverse cancers: outcome and co-amplification network Oncotarget 6 2015 3033 3042
26. P.L. Bergsagel, W.M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma Blood 106 2005 296 303
27. K. Ikeda, T. Monden, M. Tsujie, H. Izawa, H. Yamamoto, T. Ohnishi, and et al. Cyclin D CDK4 and p16 expression in colorectal cancer Nihon Rinsho 54 1996 1054 1059
28. K. Lundgren, M. Brown, S. Pineda, J. Cuzick, J. Salter, L. Zabaglo, and et al. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study Breast Cancer Res. 14 2012 R57
29. J.H. Kim, M.J. Kang, C.U. Park, H.J. Kwak, Y. Hwang, and G.Y. Koh Amplified CDK2 and cdc2 activities in primary colorectal carcinoma Cancer 85 1999 546 553
30. J. Seong, E.J. Chung, H. Kim, G.E. Kim, N.K. Kim, S.K. Sohn, and et al. Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas Int. J. Radiat. Oncol. Biol. Phys. 45 1999 1167 1173
31. E.J. Belt, R.P. Brosens, P.M. Delis-van Diemen, H. Bril, M. Tijssen, D.F. van Essen, and et al. Cell cycle proteins predict recurrence in stage II and III colon cancer Ann. Surg. Oncol. 19 2012 S682 92
32. S. Gansauge, F. Gansauge, M. Ramadani, H. Stobbe, B. Rau, N. Harada, and et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis Cancer Res. 57 1997 1634 1637
33. Y. Dobashi, A. Goto, M. Fukayama, A. Abe, and A. Ooi Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma Int. J. Cancer 110 2004 532 541
34. R. Li, S.J. An, Z.H. Chen, G.C. Zhang, J.Q. Zhu, Q. Nie, and et al. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients Hum. Pathol. 39 2008 1792 1801
35. G. Moreno-Bueno, S. Rodríguez-Perales, C. Sánchez-Estévez, R. Marcos, D. Hardisson, J.C. Cigudosa, and et al. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer Int. J. Cancer 110 2004 194 200
36. J.A. Akervall, R.J. Michalides, H. Mineta, A. Balm, A. Borg, M.R. Dictor, and et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression Cancer 79 1997 380 389
37. R.J. Michalides, N.M. van Veelen, P.M. Kristel, A.A. Hart, B.M. Loftus, F.J. Hilgers, and et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck Arch. Otolaryngol. Head Neck Surg. 123 1997 497 502
38. A. Shaye, A. Sahin, Q. Hao, K. Hunt, K. Keyomarsi, and I. Bedrosian Cyclin E deregulation is an early event in the development of breast cancer Breast Cancer Res. Treat. 115 2009 651 659
39. A. Wang, N. Yoshimi, M. Suzui, A. Yamauchi, M. Tarao, and H. Mori Different expression patterns of cyclins A, D1 and E in human colorectal cancer J. Cancer Res. Clin. Oncol. 122 1996 122 126
40. kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study World J. Gastroenterol. 11 2005 5057 5060
41. N. Nakayama, K. Nakayama, Y. Shamima, M. Ishikawa, A. Katagiri, K. Iida, and et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer Cancer 116 2010 2621 2634
42. A.M. Karst, P.M. Jones, N. Vena, A.H. Ligon, J.F. Liu, M.S. Hirsch, and et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers Cancer Res. 74 2014 1141 1152
43. E. Kuhn, A. Bahadirli-Talbott, and Ie-M. Shih Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma Mod. Pathol. 27 2014 1014 1019
44. D. Wołowiec, M. Benchaib, P. Pernas, P. Deviller, C. Souchier, R. Rimokh, and et al. Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias: comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue Leukemia 9 1995 1382 1388
45. M. Erlanson, C. Portin, B. Linderholm, J. Lindh, G. Roos, and G. Landberg Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications Blood 92 1998 770 777
46. M. Furihata, T. Ishikawa, A. Inoue, C. Yoshikawa, H. Sonobe, Y. Ohtsuki, and et al. Determination of the prognostic significance of unscheduled cyclin A overexpression in patients with esophageal squamous cell carcinoma Clin. Cancer Res. 2 1996 1781 1785
47. Y. Chao, Y.L. Shih, J.H. Chiu, G.Y. Chau, W.Y. Lui, W.K. Yang, and et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma Cancer Res. 58 1998 985 990
48. A. Nar, O. Ozen, N.B. Tutuncu, and B. Demirhan Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma Med. Oncol. 29 2012 294 300
49. S. Santala, A. Talvensaari-Mattila, Y. Soini, M. Honkavuori-Toivola, and M. Santala High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma Tumour Biol. 35 2014 5395 5399
50. R.L. Huuhtanen, C.P. Blomqvist, T.O. Böhling, T.A. Wiklund, E.J. Tukiainen, M. Virolainen, and et al. Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness Cancer Res. 59 1999 2885 2890
51. K. Aaltonen, R.-M. Amini, P. Heikkilä, K. Aittomäki, A. Tamminen, H. Nevanlinna, and et al. High cyclin B1 expression is associated with poor survival in breast cancer Br. J. Cancer 100 2009 1055 1060
52. T. Suzuki, T. Urano, Y. Miki, T. Moriya, J. Akahira, T. Ishida, and et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor Cancer Sci. 98 2007 644 651
53. J.C. Soria, S.J. Jang, F.R. Khuri, K. Hassan, D. Liu, W.K. Hong, and et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication Cancer Res. 60 2000 4000 4004
54. M.D. Begnami, J.H. Fregnani, S. Nonogaki, and F.A. Soares Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication Hum. Pathol. 41 2010 1120 1127
55. H. Murakami, M. Furihata, Y. Ohtsuki, and S. Ogoshi Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma Virchows Arch. 434 1999 153 158
56. H.G. Drexler Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells Leukemia 12 1998 845 859
57. CIP1/WAF are predictors of Hodgkin lymphoma outcome Clin. Cancer Res. 21 2015 5164 5172
58. INK4 expression in nonsmall cell lung carcinoma Cancer 80 1997 389 395
59. J. Tsihlias, L. Kapusta, and J. Slingerland The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer Annu. Rev. Med. 50 1999 401 423
60. INK4a expression in resected non-small cell lung tumors Cancer Res. 56 1996 3415 3420
61. C.J. Jennings, B. Murer, A. O'Grady, L.M. Hearn, B.J. Harvey, E.W. Kay, and et al. Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients Br. J. Cancer 113 2015 69 75
62. O. Straume, and L.A. Akslen Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma Int. J. Cancer 74 1997 535 539
63. INK4a expression in retinoblastoma: a marker of differentiation grade Diagn. Pathol. 9 2014 180
64. INK4a overexpression and survival in osteosarcoma patients: a meta analysis Int. J. Clin. Exp. Pathol. 7 2014 6091 6096
65. M. Jiang, Z.M. Shao, J. Wu, J.S. Lu, L.M. Yu, J.D. Yuan, and et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis Int. J. Cancer 74 1997 529 534
66. WAF1/CIP1 expression correlates with disease progression in gastric carcinoma Br. J. Cancer 75 11 1997 1617 1620
67. Y. Gomyo, M. Ikeda, M. Osaki, S. Tatebe, S. Tsujitani, M. Ikeguchi, and et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma Cancer 79 1997 2067 2072
68. K. Aoyagi, K. Koufuji, S. Yano, N. Murakami, M. Miyagi, A. Koga, and et al. The expression of p53, p21 and TGF β1 in gastric carcinoma Kurume Med. J. 50 2003 1 7
69. T.K. Zirbes, S.E. Baldus, S.P. Moenig, S. Nolden, D. Kunze, S.T. Shafizadeh, and et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer Int. J. Cancer 89 2000 14 18
70. WAF1/CIP1 are associated with metastasis in colorectal carcinomas Hepatogastroenterology. 52 2005 1421 1426
71. I.K. Bukholm, and J.M. Nesland Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas Virchows Arch. 436 2000 224 228
72. J. Backe, A.M. Gassel, K. Hauber, S. Krebs, J. Bartek, H. Caffier, and et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein Int. J. Gynecol. Pathol. 16 1997 361 368
73. K. Ito, H. Sasano, G. Matsunaga, S. Sato, A. Yajima, S. Nasim, and et al. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma J. Pathol. 183 3 1997 318 324
74. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients Nat. Med. 3 1997 222 225
75. M. Loda, B. Cukor, S.W. Tam, P. Lavin, M. Fiorentino, G.F. Draetta, and et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas Nat. Med. 3 1997 231 234
76. Kip1 as a prognostic factor in breast cancer: a systematic review and meta-analysis J. Cell. Mol. Med. 14 2010 944 953
77. M. Mori, K. Mimori, T. Shiraishi, S. Tanaka, H. Ueo, K. Sugimachi, and et al. p27 expression and gastric carcinoma Nat. Med. 3 1997 593
78. S.P. Singh, J. Lipman, H. Goldman, F.H. Ellis Jr., L. Aizenman, M.G. Cangi, and et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma Cancer Res. 58 1998 1730 1735
79. Kip1 protein in human prostate cancer correlates with tumor grade Clin. Cancer Res. 3 1997 2269 2274
80. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma Cancer Res. 58 1998 542 548
81. R.M. Yang, J. Naitoh, M. Murphy, H.J. Wang, J. Phillipson, J.B. deKernion, and et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer J. Urol. 159 1998 941 945
82. K. Li, M.K. Chen, J. Situ, W.T. Huang, Z.L. Su, D. He, and et al. Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery Chin. Med. J. (Engl.) 126 2013 82 87
83. V. Ananthanarayanan, R.J. Deaton, A. Amatya, V. Macias, E. Luther, A. Kajdacsy-Balla, and et al. Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays Hum. Pathol. 42 2011 873 881
84. H.S. Kim, H.S. Lee, K.H. Nam, J. Choi, and W.H. Kim p27 Loss is associated with poor prognosis in gastroenteropancreatic neuroendocrine tumors Cancer Res. Treat. 46 2014 383 392
85. KIP2 mRNA in human bladder cancer Br. J. Cancer 83 2000 626 631
86. KIP2 in human colorectal carcinoma Int. J. Oncol. 19 2001 39 47
87. H. Guo, K. Nan, T. Hu, J. Meng, W. Hui, X. Zhang, and et al. Prognostic significance of co-expression of nm23 and p57 protein in hepatocellular carcinoma Hepatol Res. 40 2010 1107 1116
88. Y. Ito, T. Takeda, K. Wakasa, M. Tsujimoto, and N. Matsuura Expression of p57/Kip2 protein in pancreatic adenocarcinoma Pancreas 23 2001 246 250
89. kip2 and its clinical relevance in epithelial ovarian tumors Anticancer Res. 22 2002 3191 3196
90. M.H. Khouja, M. Baekelandt, J.M. Nesland, and R. Holm The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma Int. J. Gynecol. Pathol. 26 2007 418 425
91. M.I. Gutiérrez, A.K. Siraj, M.M. Ibrahim, A. Hussain, and K. Bhatia Childhood and adult ALL: differences in epigenetic lesions associated with cell cycle genes Am. J. Hematol. 80 2005 158 160
92. L. Shen, M. Toyota, Y. Kondo, T. Obata, S. Daniel, S. Pierce, and et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia Blood 101 2003 4131 4136
93. C. Abdullah, X. Wang, and D. Becker Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma Cell Cycle 10 2011 977 988
94. M.Y. Zhao, A. Auerbach, A.M. D'Costa, A.P. Rapoport, A.M. Burger, E.A. Sausville, and et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy Clin. Cancer Res. 15 2009 1708 1720
95. J. Georgieva, P. Sinha, and D. Schadendorf Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions J. Clin. Pathol. 54 2001 229 235
96. D. Zheng, Y.Y. Cho, A.T. Lau, J. Zhang, W.Y. Ma, A.M. Bode, and et al. Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation Cancer Res. 68 18 2008 7650 7660
97. T.H. Cheung, M.M. Yu, K.W. Lo, S.F. Yim, T.K. Chung, and Y.F. Wong Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix Cancer Lett. 166 2001 199 206
98. K.S. Smalley, R. Contractor, T.K. Nguyen, M. Xiao, R. Edwards, V. Muthusamy, and et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression Cancer Res. 68 2008 5743 5752
99. E.E. Schmidt, K. Ichimura, G. Reifenberger, and V.P. Collins CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas Cancer Res. 54 1994 6321 6324
100. G. Wei, F. Lonardo, T. Ueda, T. Kim, A.G. Huvos, J.H. Healey, and et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons Int. J. Cancer 80 1999 199 204
101. J.S. Wunder, K. Eppert, S.R. Burrow, N. Gokgoz, R.S. Bell, and I.L. Andrulis Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas Oncogene 18 1999 783 788 (Erratum in: Oncogene 2000;19:1734)
102. S. Lee, H. Park, S.Y. Ha, K.Y. Paik, S.E. Lee, J.M. Kim, and et al. CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen PLoS One 9 2014 e99452
103. S. Park, J. Lee, I.G. Do, J. Jang, K. Rho, S. Ahn, and et al. Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling Sci. Rep. 4 2014 3623
104. Q. Liang, L. Li, J. Zhang, Y. Lei, L. Wang, D.X. Liu, and et al. CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression Sci. Rep. 3 2013 2932
105. J.P. Eggers, P.M. Grandgenett, E.C. Collisson, M.E. Lewallen, J. Tremayne, P.K. Singh, and et al. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras Clin. Cancer Res. 17 2011 6140 6150
106. Z. Levacque, J.L. Rosales, and K.Y. Lee Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients Cell Cycle 11 2012 4093 4095
107. J.F. Costello, C. Plass, W. Arap, V.M. Chapman, W.A. Held, M.S. Berger, and et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA Cancer Res. 57 1997 1250 1254
108. J. Easton, T. Wei, J.M. Lahti, and V.J. Kidd Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma Cancer Res. 58 1998 2624 2632
109. M. Chilosi, C. Doglioni, Z. Yan, M. Lestani, F. Menestrina, C. Sorio, and et al. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia Am. J. Pathol. 152 1998 209 217
110. M.Y. Kim, S.I. Han, and S.C. Lim Roles of cyclin-dependent kinase 8 and β-catenin in the oncogenesis and progression of gastric adenocarcinoma Int. J. Oncol. 38 2011 1375 1383
111. A.S. Adler, M.L. McCleland, T. Truong, S. Lau, Z. Modrusan, T.M. Soukup, and et al. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency Cancer Res. 72 2012 2129 2139
112. R. Firestein, A.J. Bass, S.Y. Kim, I.F. Dunn, S.J. Silver, I. Guney, and et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity Nature 455 2008 547 551
113. R. Firestein, K. Shima, K. Nosho, N. Irahara, Y. Baba, E. Bojarski, and et al. CDK8 expression in 470 colorectal cancers in relation to β-catenin activation, other molecular alterations and patient survival Int. J. Cancer 126 2010 2863 2873
114. J.O. Seo, S.I. Han, and S.C. Lim Role of CDK8 and β-catenin in colorectal adenocarcinoma Oncol. Rep. 24 2010 285 291
115. G. De Falco, C. Bellan, A. D'Amuri, G. Angeloni, E. Leucci, A. Giordano, and et al. Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors Cancer Biol. Ther. 4 2005 277 281
116. Z. Duan, J. Zhang, E. Choy, D. Harmon, X. Liu, P. Nielsen, and et al. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation Clin. Cancer Res. 18 2012 4580 4588
117. H. Miyagaki, M. Yamasaki, H. Miyata, T. Takahashi, Y. Kurokawa, K. Nakajima, and et al. Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma Br. J. Cancer 106 2012 947 954
118. F. Mendrzyk, B. Radlwimmer, S. Joos, F. Kokocinski, A. Benner, D.E. Stange, and et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma J. Clin. Oncol. 23 2005 8853 8862
119. U. Asghar, A.K. Witkiewicz, N.C. Turner, and E.S. Knudsen The history and future of targeting cyclin-dependent kinases in cancer therapy Nat. Rev. Drug Discov. 14 2015 130 146
120. R. Roskoski Jr. ERK1/2 MAP kinases: structure, function, and regulation Pharmacol. Res. 66 2012 105 143
121. N.R. Brown, M.E. Noble, J.A. Endicott, and L.N. Johnson The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases Nat. Cell Biol. 1 1999 438 443
122. N.R. Brown, S. Korolchuk, M.P. Martin, W.A. Stanley, R. Moukhametzianov, M.E. Noble, and et al. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK Nat. Commun. 6 2015 6769
123. S.S. Taylor, E. Radzio-Andzelm, and T. Hunter How do protein kinases discriminate between serine/threonine and tyrosine?: Structural insights from the insulin receptor protein-tyrosine kinase FASEB J. 9 1995 1255 1266
124. S.K. Hanks, A.M. Quinn, and T. Hunter The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 241 1988 42 52
125. S.K. Hanks, and T. Hunter Protein kinases 6: The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification FASEB J. 9 1995 576 596
126. D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, V.A. Ashford, N.H. Xuong, S.S. Taylor, and et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 407 414
127. D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, N.H. Xuong, S.S. Taylor, and J.M. Sowadski Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 414 420
128. S.S. Taylor, and A.P. Kornev Protein kinases: evolution of dynamic regulatory proteins Trends Biochem. Sci. 36 2011 65 77
129. R. Roskoski Jr. A historical overview of protein kinases and their targeted small molecule inhibitors Pharmacol. Res. 100 2015 1 23
130. D.M. Jacobsen, Z.Q. Bao, P. O'Brien, C.L. Brooks 3rd, and M.A. Young Price to be paid for two-metal catalysis: magnesium ions that accelerate chemistry unavoidably limit product release from a protein kinase J. Am. Chem. Soc. 134 2012 15357 15370
131. R. Roskoski Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors Pharmacol. Res. 94 2015 9 25
132. K.Y. Cheng, M.E. Noble, V. Skamnaki, N.R. Brown, E.D. Lowe, L. Kontogiannis, and et al. The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition J. Biol. Chem. 281 2006 23167 23179
133. A.C. Hengge Mechanistic studies on enzyme-catalyzed phosphoryl transfer Adv. Phys. Org. Chem. 40 2005 49 108
134. V.L. Schramm Enzymatic transition states and transition state analog design Annu. Rev. Biochem 67 1998 693 720
135. V.L. Schramm Transition States, analogues, and drug development ACS Chem. Biol. 8 2013 71 81
136. M. Valiev, J. Yang, J.A. Adams, S.S. Taylor, and J.H. Weare Phosphorylation reaction in cAPK protein kinase-free energy quantum mechanical/molecular mechanics simulations J. Phys. Chem. 111 2007 13455 13464 (Erratum in: J. Phys. Chem. 2010;114:6763)
137. Y. Cheng, Y. Zhang, and J.A. McCammon How does the cAMP-dependent protein kinase catalyze the phosphorylation reaction: an ab initio QM/MM study J. Am. Chem. Soc. 127 2005 1553 1562
138. Z.Q. Bao, D.M. Jacobsen, and M.A. Young Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis Structure 19 2011 675 690
139. A. Cook, E.D. Lowe, E.D. Chrysina, V.T. Skamnaki, N.G. Oikonomakos, and L.N. Johnson Structural studies on phospho-CDK2/cyclin A bound to nitrate, a transition state analogue: implications for the protein kinase mechanism Biochemistry 41 2002 7301 7311
140. L. Pauling Chemical achievement and hope for the future Am. Sci. 36 1948 51 58
141. T.L. Amyes, and J.P. Richard Specificity in transition state binding: the Pauling model revisited Biochemistry 52 2013 2021 2035
142. A.P. Kornev, N.M. Haste, S.S. Taylor, and L.F. Ten Eyck Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc. Natl. Acad. Sci. U. S. A. 103 2006 17783 17788
143. A.P. Kornev, S.S. Taylor, and L.F. Ten Eyck A helix scaffold for the assembly of active protein kinases Proc. Natl. Acad. Sci. U. S. A. 105 2008 14377 14382
144. H.S. Meharena, P. Chang, M.M. Keshwani, K. Oruganty, A.K. Nene, N. Kannan, and et al. Deciphering the structural basis of eukaryotic protein kinase regulation PLoS Biol. 11 2013 e1001680
145. R. Roskoski Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes Pharmacol. Res. 103 2016 26 48
146. K. Shah, Y. Liu, C. Deirmengian, and K.M. Shokat Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates Proc. Natl. Acad. Sci. U. S. A. 94 1997 3565 3570
147. Y. Liu, K. Shah, F. Yang, L. Witucki, and K.M. Shokat A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src Bioorg. Med.Chem. 6 1998 1219 1226
148. U. Schulze-Gahmen, H.L. De Bondt, and S.H. Kim High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design J. Med. Chem. 39 1996 4540 4546
149. P.D. Jeffrey, A.A. Russo, K. Polyak, E. Gibbs, J. Hurwitz, J. Massagué, and et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex Nature 376 1995 313 320
150. A.A. Russo, P.D. Jeffrey, and N.P. Pavletich Structural basis of cyclin-dependent kinase activation by phosphorylation Nat. Struct. Biol. 3 1996 696 700
151. H. Higashi, I. Suzuki-Takahashi, S. Saitoh, K. Segawa, Y. Taya, A. Okuyama, and et al. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H Eur. J. Biochem. 237 1996 460 467
152. N.R. Brown, M.E. Noble, A.M. Lawrie, M.C. Morris, P. Tunnah, G. Divita, and et al. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity J. Biol. Chem. 274 1999 8746 8756
153. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex Nature 382 1996 325 331
154. J.W. Harper, S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.H. Tsai, P. Zhang, and et al. Inhibition of cyclin-dependent kinases by p21 Mol. Biol. Cell 6 1995 387 400
155. P.D. Jeffrey, L. Tong, and N.P. Pavletich Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors Genes Dev. 14 2000 3115 3125
156. INK4a Nature 395 1998 237 243
157. A. Plückthun Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy Annu. Rev. Pharmacol. Toxicol. 55 2015 489 511
158. Q. Zhou, T. Li, and D.H. Price RNA polymerase II elongation control Annu. Rev. Biochem. 81 2012 119 143
159. J. Kohoutek P-TEFb- the final frontier Cell Div. 4 2009 19
160. J.E. Karp, B.D. Smith, L.S. Resar, J.M. Greer, A. Blackford, M. Zhao, and et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias Blood 117 12 2011 3302 3310
161. J.F. Zeidner, M.C. Foster, A.L. Blackford, M.R. Litzow, L.E. Morris, S.A. Strickland, and et al. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7 + 3) in newly diagnosed acute myeloid leukemia Haematologica 100 2015 1172 1179
162. B.A. Christian, M.R. Grever, J.C. Byrd, and T.S. Lin Flavopiridol in the treatment of chronic lymphocytic leukemia Curr. Opin. Oncol. 19 2007 573 578
163. T.S. Lin, A.S. Ruppert, A.J. Johnson, B. Fischer, N.A. Heerema, L.A. Andritsos, and et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease J. Clin. Oncol. 27 2009 6012 6018
164. S. George, B.S. Kasimis, J. Cogswell, P. Schwarzenberger, G.I. Shapiro, P. Fidias, and et al. Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer Clin. Lung Cancer 9 2008 160 165
165. M.C. Lanasa, L. Andritsos, J.R. Brown, J. Gabrilove, F. Caligaris-Cappio, P. Ghia, and et al. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia Leuk. Res. 39 2015 495 500
166. O.P. van Linden, A.J. Kooistra, R. Leurs, I.J. de Esch, and C. de Graaf KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space J. Med. Chem. 57 2014 249 277
167. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, and et al. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
168. P.M. Fracasso, K.J. Williams, R.C. Chen, J. Picus, C.X. Ma, M.J. Ellis, and et al. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies Cancer Chemother. Pharmacol. 67 2011 1225 1237
169. J. Kortmansky, M.A. Shah, A. Kaubisch, A. Weyerbacher, S. Yi, W. Tong, and et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors J. Clin. Oncol. 23 2005 1875 1884
170. S.J. Hotte, A. Oza, E.W. Winquist, M. Moore, E.X. Chen, S. Brown, and et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study Ann. Oncol. 17 2006 334 340
171. I. Gojo, A. Perl, S. Luger, M.R. Baer, K.J. Norsworthy, K.S. Bauer, and et al. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome Invest. New Drugs 31 2013 1217 1227
172. S.R. Whittaker, M.I. Walton, M.D. Garrett, and P. Workman The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway Cancer Res. 64 2004 262 272
173. W.S. Hsieh, R. Soo, B.K. Peh, T. Loh, D. Dong, D. Soh, and et al. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer Clin. Cancer Res. 15 2009 1435 1442
174. C. Le Tourneau, S. Faivre, V. Laurence, C. Delbaldo, K. Vera, V. Girre, and et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies Eur. J. Cancer 46 2010 3243 3250
175. L.M. Gelbert, S. Cai, X. Lin, C. Sanchez-Martinez, M. Del Prado, M.J. Lallena, and et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent antitumor activities alone/in combination with gemcitabine Invest. New Drugs 32 2014 825 837
176. N. Vidula, and H.S. Rugo Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data Clin. Breast Cancer 16 2016 8 17
177. L. Santo, S. Vallet, T. Hideshima, D. Cirstea, H. Ikeda, S. Pozzi, and et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition Oncogene 2 9 2010 2325 2336
178. D. Mahadevan, R. Plummer, M.S. Squires, D. Rensvold, S. Kurtin, C. Pretzinger, and et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors Ann. Oncol. 22 2011 2137 2143
179. E.X. Chen, S. Hotte, H. Hirte, L.L. Siu, J. Lyons, M. Squires, and et al. A phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC clinical trials group IND 177 Br. J. Cancer 111 2014 2262 2267
180. R.N. Misra, H.Y. Xiao, K.S. Kim, S. Lu, W.C. Han, S.A. Barbosa, and et al. N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent J. Med. Chem. 47 2004 1719 1728 (Erratum in: J Med Chem 2015;58:7609)
181. E.I. Heath, K. Bible, R.E. Martell, D.C. Adelman, and P.M. Lorusso A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors Invest. New Drugs 26 2008 59 65
182. W.G. Tong, R. Chen, W. Plunkett, D. Siegel, R. Sinha, R.D. Harvey, and et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma J. Clin. Oncol. 28 2010 3015 3022
183. D. Parry, T. Guzi, F. Shanahan, N. Davis, D. Prabhavalkar, D. Wiswell, and et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor Mol. Cancer Ther. 9 2010 2344 2353
184. K. Paruch, M.P. Dwyer, C. Alvarez, C. Brown, T.Y. Chan, R.J. Doll, and et al. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases ACS Med Chem Lett 1 2010 204 208
185. J.J. Nemunaitis, K.A. Small, P. Kirschmeier, D. Zhang, Y. Zhu, Y.M. Jou, and et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies J. Transl. Med. 11 2013 259
186. J.J. Stephenson, J. Nemunaitis, A.A. Joy, J.C. Martin, Y.M. Jou, D. Zhang, and et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer Lung Cancer 83 2014 219 223
187. M.M. Mita, A.A. Joy, A. Mita, K. Sankhala, Y.M. Jou, D. Zhang, and et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer Clin. Breast Cancer 14 2014 169 176
188. J. Flynn, J. Jones, A.J. Johnson, L. Andritsos, K. Maddocks, S. Jaglowski, and et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia Leukemia 29 2015 1524 1529
189. Z. Mitri, C. Karakas, C. Wei, B. Briones, H. Simmons, N. Ibrahim, and et al. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer Invest. New Drugs 33 2015 890 894
190. C.J. Sherr, D. Beach, and G.I. Shapiro Targeting CDK4 and CDK6: from discovery to therapy Cancer Discov. 2015 (Epub ahead of print)
191. J. Rader, M.R. Russell, L.S. Hart, M.S. Nakazawa, L.T. Belcastro, D. Martinez, and et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma Clin. Cancer Res. 19 2013 6173 6182
192. K.S. Joshi, M.J. Rathos, R.D. Joshi, M. Sivakumar, M. Mascarenhas, S. Kamble, and et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P 276-00 Mol. Cancer Ther. 6 2007 918 925
193. S.M. Manohar, M.J. Rathos, V. Sonawane, S.V. Rao, and K.S. Joshi Cyclin-dependent kinase inhibitor, P 276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription Leuk. Res. 35 2011 821 830
194. K.S. Joshi, M.J. Rathos, P. Mahajan, V. Wagh, S. Shenoy, D. Bhatia, and et al. P 276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models Mol. Cancer Ther. 6 2007 926 934
195. R.D. Cassaday, A. Goy, S. Advani, P. Chawla, R. Nachankar, M. Gandhi, and et al. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P 276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma Clin. Lymphoma Myeloma Leuk. 15 2015 392 397
196. D.W. Fry, P.J. Harvey, P.R. Keller, W.L. Elliott, M. Meade, E. Trachet, and et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol. Cancer Ther. 3 2004 1427 1438
197. S.N. VanderWel, P.J. Harvey, D.J. McNamara, J.T. Repine, P.R. Keller, J. Quin 3rd, and et al. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4 J. Med. Chem. 48 2005 2371 2387
198. P.L. Toogood, P.J. Harvey, J.T. Repine, D.J. Sheehan, S.N. VanderWel, H. Zhou, and et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 J. Med. Chem. 48 2005 2388 2406
199. R.S. Finn, J. Dering, D. Conklin, O. Kalous, D.J. Cohen, A.J. Desai, and et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast Cancer Res. 11 2009 R77
200. T.W. Miller, J.M. Balko, E.M. Fox, Z. Ghazoui, A. Dunbier, H. Anderson, and et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer Cancer Discov. 1 2011 338 351
201. R.S. Finn, J.P. Crown, I. Lang, K. Boer, I.M. Bondarenko, S.O. Kulyk, and et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol. 16 2015 25 35
202. N.C. Turner, J. Ro, F. André, S. Loi, S. Verma, H. Iwata, and et al. Palbociclib in hormone-receptor-positive advanced breast cancer N. Engl. J. Med. 373 2015 209 219
203. T.L. Nero, C.J. Morton, J.K. Holien, J. Wielens, and M.W. Parker Oncogenic protein interfaces: small molecules, big challenges Nat. Rev. Cancer 14 2014 248 262
204. L. Jin, W. Wang, and G. Fang Targeting protein-protein interaction by small molecules Annu. Rev. Pharmacol. Toxicol. 54 2014 435 456
205. M.R. Arkin, Y. Tang, and J.A. Wells Small-molecule inhibitors of protein-protein interactions: progressing toward the reality Chem. Biol. 21 2014 1102 1114
206. R. Roskoski Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition Pharmacol. Res. 68 2013 68 94
207. N. Mendoza, S. Fong, J. Marsters, H. Koeppen, R. Schwall, and D. Wickramasinghe Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth Cancer Res. 63 2003 1020 1024
208. N. Canela, M. Orzáez, R. Fucho, F. Mateo, R. Gutierrez, A. Pineda-Lucena, and et al. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A J. Biol. Chem. 281 2006 35942 35953
209. K. Nasmyth A prize for proliferation Cell 107 2001 689 701
210. L.H. Hartwell, J. Culotti, and B. Reid Genetic control of the cell-division cycle in yeast. I. Detection of mutants Proc. Natl. Acad. Sci. U. S. A. 66 1970 352 359
211. P. Nurse Genetic control of cell size at cell division in yeast Nature 256 1975 547 551
212. T. Evans, E.T. Rosenthal, J. Youngblom, D. Distel, and Hunt T. Cyclin a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division Cell 33 1983 389 396
213. H. Rajagopalan, and C. Lengauer Aneuploidy and cancer Nature 432 2004 338 341
214. A.M. Senderowicz, and E.A. Sausville Preclinical and clinical development of cyclin-dependent kinase modulators J. Natl. Cancer Inst. 92 2000 376 387
215. G. Kaur, M. Stetler-Stevenson, S. Sebers, P. Worland, H. Sedlacek, C. Myers, and et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275 J. Natl. Cancer Inst. 84 1992 1736 1740
216. F.Y. Wei, K. Nagashima, T. Ohshima, Y. Saheki, Y.F. Lu, M. Matsushita, and et al. Cdk5-dependent regulation of glucose-stimulated insulin secretion Nat. Med. 11 2005 1104 1108
217. A. Mullard 2015 FDA drug approvals Nat. Rev. Drug Discov. 15 2016 73 76
218. H.M. Kantarjian, T. Fojo, M. Mathisen, and L.A. Zwelling Cancer drugs in the United States: justum pretium-the just price J. Clin. Oncol. 31 2013 3600 3604
219. S.Y. Zafar, J.M. Peppercorn, D. Schrag, D.H. Taylor, A.M. Goetzinger, X. Zhong, and et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience Oncologist 18 2013 381 390
220. R. Roskoski Jr. Fritz lipmann (1899-1986): an appreciation Trends Biochem. Sci. 12 1987 136 138